Table 2.
Ongoing clinical trials involving γδ T cells
| Clinical trial ID (NCT) | Disease type | Treatment | Trial phase |
|---|---|---|---|
| In vivo expansion | |||
| 03862833 | Leukaemia | Zoledronic acid+IL‐2 | I |
| 01404742 | Neuroblastoma | Zoledronic acid +IL‐2 | I |
| 00588913 | Kidney cancer, lung metastasis | Zoledronic acid + IL‐2 Autologous activated lymphocytes | I/II |
| 02781805 | Breast cancer | Alendronate | I |
| Ex vivo expansion | |||
| 03533816 | AML, CML, ALL, MDS | EAGD T‐cell infusion | I |
| 03183206 | Breast cancer | Cryosurgery/IRE + γδ T‐cell infusion | I/II |
| 03183232 | Lung cancer | Cryosurgery/IRE + γδ T‐cell infusion | I/II |
| 03183219 | Liver cancer | Cryosurgery/IRE + γδ T‐cell infusion | I/II |
| 03180437 | Pancreatic cancer | Cryosurgery/IRE + γδ T‐cell infusion | I/II |
| 02418481 | Breast cancer | γδ T‐cell infusion | I/II |
| 02425748 | Lung cancer | γδ T‐cell infusion | I/II |
| 02425735 | Liver cancer | γδ T‐cell infusion | I/II |
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia; EAGD, expanded/activated γδ T cell; IRE, irreversible electroporation; MDS, myelodysplastic syndrome.